Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review

In this review, we describe previous basic and clinical studies on autonomous aldosterone production. Over the past decades, mineralocorticoid receptor antagonists (MRAs) have been found to concentration-dependently inhibit steroidogenesis in different degrees. However, many studies have proven the...

Full description

Bibliographic Details
Main Authors:	Xurong Mai, Mitsuhiro Kometani, Takashi Yoneda
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	International Journal of Molecular Sciences
Subjects:	primary aldosteronism remission mineralocorticoid receptor antagonist steroidogenesis enzyme
Online Access:	https://www.mdpi.com/1422-0067/23/22/13821

Similar Items

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2021-10-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
by: Jean Kim, et al.
Published: (2022-03-01)

Effects of chronically high levels of aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism
by: Lukas Engler, et al.
Published: (2019-04-01)

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease
by: Shinji Hagiwara, et al.
Published: (2024-01-01)

New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies
by: Cheng-Hsuan Tsai, et al.
Published: (2021-05-01)

Editorial: Expanding spectrum of primary aldosteronism: exploring new grounds
by: Norlela Sukor, et al.
Published: (2023-04-01)

Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta‐Analysis, and Meta‐Regression to Identify Modifying Factors
by: Joachim Alexandre, et al.
Published: (2019-11-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
by: Andrei Niculae, et al.
Published: (2022-03-01)

Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood
by: Bruno Griesler, et al.
Published: (2022-10-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Comparison of Echocardiographic Changes Between Surgery and Medication Treatment in Patients With Primary Aldosteronism
by: Tomomi Ueda, et al.
Published: (2022-07-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
by: Greg H. Tesch, et al.
Published: (2017-05-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
by: Josefin Henrysson, et al.
Published: (2023-02-01)

Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report
by: Reoto Kijima, et al.
Published: (2023-10-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
by: Fernet M, et al.
Published: (2018-09-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
by: Line Aas Mortensen, et al.
Published: (2017-11-01)

First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures
by: Jacopo Manso, et al.
Published: (2024-01-01)

Prevalence of aldosterone breakthrough in dogs receiving renin‐angiotensin system inhibitors for proteinuric chronic kidney disease
by: Marisa K. Ames, et al.
Published: (2022-11-01)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by: Asadur Rahman, et al.
Published: (2023-01-01)

Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction
by: Aderonke E. Igbekele, et al.
Published: (2022-08-01)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
by: Camila Q. Felipe, et al.
Published: (2022-06-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01)

Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis
by: Wei-Chieh Huang, et al.
Published: (2021-05-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
by: Pascal R. D. Clephas, et al.
Published: (2023-04-01)

Correlation of functional and radioligand binding characteristics of GPER ligands confirming aldosterone as a GPER agonist
by: Qingming Ding, et al.
Published: (2022-10-01)

Aldosterone: Essential for Life but Damaging to the Vascular Endothelium
by: Michael Crompton, et al.
Published: (2023-06-01)

Influence of Different Treatment Strategies on New‐Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort‐Based Study
by: Chien‐Ting Pan, et al.
Published: (2020-03-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
by: Nappi J, et al.
Published: (2011-06-01)